bioRxivMicrobiologyPreprint
Development of a replication-defective MPXV platform for fundamental and therapeutic research
Jiannan CheniD, Linyong HuiD, Ning ShiiD, J.H. TianiD, Yuyi Zhang, Sicheng TianiD, Xinyu Cao, Zhuo HaiD, Qiliang CaiiD, Yongxu Lu, Geoffrey L. SmithiD, Youhua XieiD, Huijun Lu, Ping ZhangiD, Rong ZhangiD
Abstract
The recent global outbreaks of mpox highlight the urgent need for both fundamental research and antiviral development. However, studying monkeypox virus (MPXV), with its large and complex genome, remains challenging due to the requirement for high-containment facilities. Here, we describe a novel strategy for de novo assembly of MPXV clade IIb genomes in bacterial artificial chromosomes using transformation-associated recombination cloning. Leveraging CRISPR-Cas9 and Lambda Red recombination, we engineered replication-defective MPXV particles with dual deletions of OPG96 (M2R) and OPG158 (A32.5L)--genes essential for virion assembly, that are capable of recapitulating key stages of the viral life cycle. Our work demonstrates the utility of replication-defective MPXV particles as a reliable platform for high-throughput antiviral discovery, offering significant advantages for both fundamental virology studies and therapeutic development against orthopoxviruses.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An Efficient and Safe Trans-complementation System for MPXV Mimicking Authentic Viral Infection
- Molecular Architecture of Monkeypox Mature Virus
Ye Hong, Baoying Huang, … Sai Li·Cell DiscoveryPeer-reviewed·Oct 22, 2024
- Drug screen reveals new potent host-targeted antivirals against Mpox virus
Arjit Vijey Jeyachandran, Anne K. Zaiss, … Vaithilingaraja Arumugaswami·bioRxiv·May 2, 2025
- A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge
A. W. Freyn, C. Atyeo, … B. Moss·bioRxiv·Dec 17, 2022
- Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus
- Polyvalent mRNA vaccination elicited potent immune response to monkeypox surface antigens
Z. Fang, P. A. Renauer, … S. Chen·bioRxiv·Nov 29, 2022